A detailed history of Wells Fargo & Company transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 350 shares of RLMD stock, worth $952. This represents 0.0% of its overall portfolio holdings.

Number of Shares
350
Previous 350 -0.0%
Holding current value
$952
Previous $1,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$2.93 - $4.94 $565 - $953
-193 Reduced 35.54%
350 $1,000
Q1 2024

May 10, 2024

BUY
$3.1 - $6.8 $9 - $20
3 Added 0.56%
543 $2,000
Q4 2023

Feb 09, 2024

BUY
$2.45 - $4.22 $24 - $42
10 Added 1.89%
540 $2,000
Q3 2023

Nov 13, 2023

SELL
$2.48 - $3.79 $9 - $15
-4 Reduced 0.75%
530 $1,000
Q2 2023

Aug 15, 2023

SELL
$2.22 - $3.54 $10,724 - $17,101
-4,831 Reduced 90.05%
534 $1,000
Q1 2023

May 12, 2023

BUY
$2.24 - $4.76 $9,457 - $20,096
4,222 Added 369.38%
5,365 $12,000
Q4 2022

Feb 13, 2023

SELL
$2.17 - $35.84 $44,940 - $742,246
-20,710 Reduced 94.77%
1,143 $3,000
Q3 2022

Nov 14, 2022

SELL
$18.3 - $37.02 $58,175 - $117,686
-3,179 Reduced 12.7%
21,853 $809,000
Q2 2022

Aug 12, 2022

BUY
$16.5 - $30.34 $13,233 - $24,332
802 Added 3.31%
25,032 $476,000
Q1 2022

May 16, 2022

BUY
$16.72 - $26.99 $264,861 - $427,548
15,841 Added 188.83%
24,230 $654,000
Q4 2021

Feb 14, 2022

BUY
$16.93 - $26.82 $120,473 - $190,851
7,116 Added 558.99%
8,389 $189,000
Q3 2021

Nov 15, 2021

SELL
$21.86 - $34.77 $180,825 - $287,617
-8,272 Reduced 86.66%
1,273 $33,000
Q2 2021

Aug 16, 2021

SELL
$29.55 - $39.15 $81,764 - $108,328
-2,767 Reduced 22.47%
9,545 $306,000
Q1 2021

May 13, 2021

SELL
$31.52 - $39.28 $971,509 - $1.21 Million
-30,822 Reduced 71.46%
12,312 $434,000
Q4 2020

Feb 09, 2021

BUY
$29.88 - $39.8 $244,687 - $325,922
8,189 Added 23.43%
43,134 $1.38 Million
Q3 2020

Nov 05, 2020

SELL
$34.42 - $43.78 $138,127 - $175,689
-4,013 Reduced 10.3%
34,945 $1.31 Million
Q2 2020

Aug 13, 2020

BUY
$31.59 - $49.98 $861,554 - $1.36 Million
27,273 Added 233.4%
38,958 $1.74 Million
Q1 2020

May 14, 2020

BUY
$23.78 - $50.12 $277,869 - $585,652
11,685 New
11,685 $399,000

Others Institutions Holding RLMD

About RELMADA THERAPEUTICS, INC.


  • Ticker RLMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,608,500
  • Market Cap $77.8M
  • Description
  • Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...
More about RLMD
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.